Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. - Wikidata - wikimedia - TriplyDB

Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.

Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.

http://www.wikidata.org/entity/Q36918248

about

Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator.Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma.Ceramide activates lysosomal cathepsin B and cathepsin D to attenuate autophagy and induces ER stress to suppress myeloid-derived suppressor cells.Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.The Role of Myeloid-Derived Suppressor Cells in Viral Infection.From identification of the BTK kinase to effective management of leukemia.Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update.The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk.Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration.Role of Bruton's tyrosine kinase in B cells and malignancies.Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.SETD1B Activates iNOS Expression in Myeloid-Derived Suppressor Cells.Cytokine Expression and Macrophage Localization in Xenograft and Allograft Tumor Models Stimulated with Lipopolysaccharide.Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies.Immunosuppressive Role of Myeloid-Derived Suppressor Cells and Therapeutic Targeting in Lung Cancer.Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy Embelin impairs the accumulation and activation of MDSCs in colitis-associated tumorigenesis

P2860

Q28076161-395F6300-0237-4728-BEFF-838AF1D7213A Q28076760-8BD99663-CB0B-4D85-B455-D8F841CC7A3B Q37308202-930A064F-A3DA-4624-9FB3-6ECF01F97E7C Q37593573-EBAEF1B1-D2B4-4EAB-8FCD-C19C9EE800A3 Q37641801-5AB6BE2B-FE92-401C-8F56-919F9AE2A6FC Q37708912-4497A356-C8A7-4B5E-BEE0-BBE8F3E824D8 Q38765458-F50C3366-B2A0-449B-94F8-9AA2D5D23C42 Q38774994-9C6873EB-4642-4EEC-8F2C-AEB5BF827AA6 Q38817591-356B8296-F0A6-4507-92D0-CDDEFF682AC1 Q39043404-821A2F93-CC43-4B1F-AC43-9639872F8862 Q39538318-98720715-76DC-4EC1-9DC0-D1C941C18F2E Q46011813-E63447C8-3C21-4F93-B9A5-AB894CCAD5F4 Q47144801-CF0B6404-6FD2-4EC9-8E97-E0056BC6383D Q49888075-8EF00395-4A16-4779-8D1C-CC55FE681B82 Q50065065-CA6EF400-B2D9-44DD-BF74-948F40281D90 Q51069953-37351521-8490-4F25-8866-60EA127F7B37 Q52310791-BCE9B157-C6E8-401D-B9EA-B331C77093DC Q52645038-E7B05FCF-8B46-44A0-90CA-D3408E134493 Q54918600-5190E6EB-2BF2-450E-B90B-A50D60F38B1E Q57817490-F44A72EA-5655-4D88-84FD-676F92457846 Q58129606-D7207E74-6A9F-4C1C-B4C3-A6810DE27B63

P2860

Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.

http://www.wikidata.org/entity/Q36918248

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Myeloid-Derived Suppressor Cel ...... Hosts by Ibrutinib Treatment.

@en

type

label

Myeloid-Derived Suppressor Cel ...... Hosts by Ibrutinib Treatment.

@en

prefLabel

Myeloid-Derived Suppressor Cel ...... Hosts by Ibrutinib Treatment.

@en

P1433

Q36918248-194AA5B3-65AF-4340-9C03-3D2F3E66F34A

P1476

Q36918248-526D5712-2F50-4BA5-8F8F-0C351A17B236

P2093

Q36918248-12068667-9594-41DA-A82A-6193ECEFD3E8

Q36918248-1E0176DF-E0E4-4636-8FD1-215EE0324DB5

Q36918248-3221E9C6-4F3F-4BCC-A47A-323E602DD1D6

Q36918248-3591FD3C-0FFB-4384-A7F2-24E67EC86AE3

Q36918248-361FE77C-3C2E-42F5-BCFD-627ECDF0BA6A

Q36918248-3B27401D-2F3E-4D36-A3FB-DC02B1577E48

Q36918248-3C23F118-3D87-4864-9D3B-C402BBE011A0

Q36918248-46692502-E08A-41DA-87A3-7AF754183CCD

Q36918248-5750C70E-7F69-48EF-A6F2-AD93803D0D9D

Q36918248-5A4B64F2-1D99-45D3-871B-21D2653AE6DF

P2860

Q36918248-02208BA8-513C-4F55-B6A4-FA3742513FBC

Q36918248-050E822B-2B78-4C89-B325-59D40BA5B1F9

Q36918248-0B33B42D-D4D8-4C68-BE20-35B8F63698E0

Q36918248-0B9CABEF-DD35-40CE-9FD9-3E1C143F4337

Q36918248-103776B4-5711-44B9-A143-643CE6E8CDDF

Q36918248-178ABDED-CF81-4FD1-A937-A2E0483A9509

Q36918248-1859A7F7-007F-4A99-AA03-39C027E03A04

Q36918248-18C459CA-D778-4D74-B728-179790E17A3A

Q36918248-1FCE5E52-CED0-4953-86B1-DFA52BF5DF27

Q36918248-207251F1-E5C7-47BF-AEE8-4AFAAA5C64C2

P304

Q36918248-36695F92-F103-4DD5-BD4A-AB7045AEB845

P31

Q36918248-30CC745D-F5E6-4965-89EF-61BCCE3D7CC5

P356

Q36918248-FB2E16B7-DFD1-4AE7-93A9-574D8429221E

P407

Q36918248-F8BC22FB-277D-4029-86E5-BF8D76E9BF09

P433

Q36918248-EDE388AE-A386-4F71-A248-8AC3FC147886

P478

Q36918248-6700BC3C-6C92-45E9-991D-7945D16E9524

P50

Q36918248-075D3392-A8C3-4B02-927C-252BAF97252F

P577

Q36918248-D4320E26-4281-4DDD-96DF-21348E1E287B

P698

Q36918248-D3545E4E-C2C6-427E-B25B-729487F131AC

P932

Q36918248-AAD4DE42-3DFD-4602-BE9A-51B5EFCBD18F

P356

0008-5472.CAN-15-1490

P1433

Cancer Research

P1476

Myeloid-Derived Suppressor Cel ...... Hosts by Ibrutinib Treatment.

@en

P2093

Amanda Campbell

http://www.w3.org/2001/XMLSchema#string

Andrew Stiff

http://www.w3.org/2001/XMLSchema#string

Bonnie Harrington

http://www.w3.org/2001/XMLSchema#string

Elizabeth McMichael

http://www.w3.org/2001/XMLSchema#string

Ian Landi

http://www.w3.org/2001/XMLSchema#string

Jason Dubovsky

http://www.w3.org/2001/XMLSchema#string

John Harrison Howard

http://www.w3.org/2001/XMLSchema#string

Karen Keller

http://www.w3.org/2001/XMLSchema#string

Kari Kendra

http://www.w3.org/2001/XMLSchema#string

Lianbo Yu

http://www.w3.org/2001/XMLSchema#string

P2860

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils

Myeloid-derived suppressor cells as regulators of the immune system

Coordinated regulation of myeloid cells by tumours

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk

The immune contexture in human tumours: impact on clinical outcome

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Tyrosine kinase Btk regulates E-selectin-mediated integrin activation and neutrophil recruitment by controlling phospholipase C (PLC) gamma2 and PI3Kgamma pathways.

Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer.

P304

2125-2136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-15-1490

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26880800

http://www.w3.org/2001/XMLSchema#string

P932

4873459

http://www.w3.org/2001/XMLSchema#string